You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 9,090,945


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 9,090,945
Title:Mean DNA copy number of chromosomal regions is of prognostic significance in cancer
Abstract: Methods for predicting a disease free time interval (DFI) for a cancer patient under consideration for initial or further chemotherapy treatment are disclosed. The methods include obtaining a biological sample from a patient and detecting a copy number of chromosome region A1 and/or C2. The mean copy number per cell is correlated with a DFI for the subject. The chemotherapy can include doxorubicin and/or L-asparaginase treatment. Also provided are kits for predicting DFI in a subject with cancer and computer readable storage media for performing the presently disclosed methods.
Inventor(s): Breen; Matthew (Apex, NC)
Assignee: North Carolina State University (Raleigh, NC)
Application Number:13/515,614
Patent Claims:1. A method for predicting the disease free time interval for a subject with a cancer under consideration for initial or further chemotherapy treatment, the method comprising: obtaining a biological sample from a canine or human subject, wherein the sample comprises a number of cells; detecting a copy number of chromosome region A1, chromosome region C2, or both chromosome region A1 and chromosome region C2 in the biological sample, wherein the detecting comprises contacting the chromosome region A1 with a first plurality of probes and/or the chromosome region C2 with a second plurality of probes, wherein the first and the second plurality of probes are labeled with different fluorescent labels, and differentially visualizing the chromosome region A1 and/or the chromosome region C2 in the biological sample by multicolor fluorescence in situ hybridization (FISH); and further wherein: in canines, chromosome region A1 comprises nucleotides 116,839,835-117,635,991 of canine chromosome 1 (CFA1) as set forth in Accession No. NC 006583 of the GENBANK.RTM. biosequence database and chromosome region C2 comprises nucleotides 41,565,280-42,426,757 of canine chromosome 6 (CFA6) as set forth in Accession No. NC.sub.--006588 of the GENBANK.RTM. biosequence database; and in humans, chromosome region A1 comprises nucleotides 43,452,745-44,221,900 of human chromosome 19 as set forth in Accession No. NC.sub.--000019 of the GENBANK.RTM. biosequence database and chromosome region C2 comprises nucleotides 1,629,295-2,350,975 of human chromosome 16 as set forth in Accession No. NC.sub.--000016 of the GENBANK.RTM. biosequence database; dividing the copy number detected for the chromosome region A1 and/or the copy number detected for the chromosome region C2 by the number of cells in the biological sample to obtain a mean copy number value for chromosome region A1, a mean copy number value for chromosome region C2, or a mean copy number value for chromosome region A1 and a mean copy number value for chromosome region C2; and correlating the mean copy number value(s) obtained for chromosome region A1 and/or chromosome region C2 with a duration of disease free interval.

2. The method of claim 1, wherein the subject has lymphoma.

3. The method of claim 2, wherein the lymphoma is non-Hodgkin's lymphoma.

4. The method of claim 1, wherein the subject is a canine.

5. The method of claim 1, wherein the biological sample comprises a biopsy.

6. The method of claim 1, wherein the biological sample comprises lymph node cells.

7. The method of claim 1, wherein the chemotherapy treatment comprises administering doxorubicin to the subject.

8. The method of claim 7, wherein the chemotherapy treatment further comprises administering L-asparaginase to the subject.

9. The method of claim 1, further comprising determining the disease free interval (DFI) by substituting the mean copy number value for A1 into Formula A, wherein Formula A is: DFI=374.1685.times.(mean copy number value for A1)-438.7572 days.

10. The method of claim 1, comprising: detecting a copy number of chromosome region C2 in the biological sample; and dividing the copy number by the number of cells in the biological sample to obtain a mean copy number value for C2.

11. The method of claim 10, wherein the detecting a copy number of chromosome region C2 comprises contacting the sample with a probe able to detect the presence of chromosome region C2 under conditions sufficient to enable hybridization of the probe to chromosome region C2.

12. The method of claim 10, further comprising determining the disease free interval (DFI) by substituting the mean copy number value for A1 and the mean copy number value for C2 into Formula AC, wherein Formula AC is: DFI=367.5094.times.(mean copy number value for A1)+228.2709.times.(mean copy number value for C2)-839.22 days.

13. The method of claim 1, wherein a mean copy number has a positive correlation with an increased disease free time interval.

14. A kit for predicting disease free time interval in a canine or human subject with lymphoma under consideration for initial or further chemotherapy treatment, the kit comprising a first probe able to detect chromosome region A1 and a second probe able to detect chromosome region C2, wherein: the first probe and the second probe are labeled with different fluorescent labels that allow differential visualization of the chromosome region A1 and the chromosome region C2 in the biological sample by multicolor fluorescence in situ hybridization (FISH); and in canines, chromosome region A1 comprises nucleotides 116,839,835-117,635,991 of canine chromosome 1 (CFA1) as set forth in Accession No. NC.sub.--006583 of the GENBANK.RTM. biosequence database and chromosome region C2 comprises nucleotides 41,565,280-42,426,757 of canine chromosome 6 (CFA6) as set forth in Accession No. NC.sub.--006588 of the GENBANK.RTM. biosequence database; and in humans, chromosome region A1 comprises nucleotides 43,452,745-44,221,900 of human chromosome 19 as set forth in Accession No. NC.sub.--000019 of the GENBANK.RTM. biosequence database and chromosome region C2 comprises nucleotides 1,629,295-2,350,975 of human chromosome 16 as set forth in Accession No. NC.sub.--000016 of the GENBANK.RTM. biosequence database.

15. A computer readable storage medium having stored thereon computer executable instructions that, when executed by a processor of a computer, control the computer to perform steps comprising: analyzing a mean copy number from chromosome region A1, a mean copy number value for chromosome region C2, or mean copy number values for both chromosome region A1 and chromosome region C2 from a biological sample obtained from a canine or human subject with a cancer, wherein: in canines, chromosome region A1 comprises nucleotides 116,839,835-117,635,991 of canine chromosome 1 (CFA1) as set forth in Accession No. NC 006583 of the GENBANK.RTM. biosequence database and chromosome region C2 comprises nucleotides 41,565,280-42,426,757 of canine chromosome 6 (CFA6) as set forth in Accession No. NC 006588 of the GENBANK.RTM. biosequence database; and in humans, chromosome region A1 comprises nucleotides 43,452,745-44,221,900 of human chromosome 19 as set forth in Accession No. NC.sub.--000019 of the GENBANK.RTM. biosequence database and chromosome region C2 comprises nucleotides 1,629,295-2,350,975 of human chromosome 16 as set forth in Accession No. NC.sub.--000016 of the GENBANK.RTM. biosequence database; and outputting a predicted disease free interval (DFI) for the canine or human subject.

16. The computer readable storage medium of claim 15, wherein the processor employs Formula A to compute the DFI, and further wherein Formula A is: DFI=374.1685.times.(mean copy number value for A1)-438.7572 days.

17. The computer readable storage medium of claim 15, comprising instructions that control the computer to perform steps comprising analyzing a mean copy number from chromosome region C2 from the biological sample.

18. The computer readable storage medium of claim 17, wherein the processor employs Formula AC to compute the DFI, and further wherein Formula AC is: DFI=367.5094.times.(mean copy number value for A1)+228.2709.times.(mean copy number value for C2)-839.22 days.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.